Erratum: CFTR is a tumor suppressor gene in murine and human intestinal cancer (Oncogene (2016) 35 (4179-4187) DOI: 10.1038/onc.2015.483);CFTR is a tumor suppressor gene in murine and human intestinal cancer

Oncogene

Volumn 35, Issue 32, 2016, Pages 4191-4199

  Than, B L N ^a   Linnekamp, J F ^b,h   Starr, T K ^a,c   Largaespada, D A ^a   Rod, A ^a   Zhang, Y ^d   Bruner, V ^a   Abrahante, J ^a   Schumann, A ^a   Luczak, T ^a   Niemczyk, A ^a   O'Sullivan, M G ^e   Medema, J P ^b   Fijneman, R J A ^f,g   Meijer, G A ^f,g   Van Den Broek, E ^f   Hodges, C A ^h   Scott, P M ^a   Vermeulen, L ^b   Cormier, R T ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

^h CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ION CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RECURRENCE; CARCINOGENESIS; CELL GROWTH; COLON; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENOTYPE; HUMAN; IMMUNE RESPONSE; INTESTINAL STEM CELL; INTESTINE CANCER; LETHALITY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE; TUMOR SUPPRESSOR GENE; ANIMAL; COLORECTAL TUMOR; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; COLON; COLORECTAL NEOPLASMS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE-FREE SURVIVAL; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICE; MUTATION; SIGNAL TRANSDUCTION;

EID: 84954570675     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2017.3     Document Type: Erratum

References (54)

1. De Lisle RC, Borowitz D. The cystic fibrosis intestine. Cold Spring Harb Perspect Med 2013; 3: a009753.
2. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-1073.
3. Pedersen SF, Stock C. Ion channels and transporters in cancer: pathophysiology, regulation, and clinical potential. Cancer Res 2013; 73: 1658-1661.
4. Neglia JP, FitzSimmons SC, Maisonneuve P, Schöni MH, Schöni-Affolter F, Corey M et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med 1995; 332: 494-499.
5. McWilliams R, Highsmith WE, Rabe KG, de Andrade M, Tordsen LA, Holtegaard LM et al. Cystic fibrosis transmembrane regulator gene carrier status is a risk factor for young onset pancreatic adenocarcinoma. Gut 2005; 54: 1661-1662.
6. Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst 2013; 105: 122-129.
7. Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell PW III, Lowenfels AB. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst 2003; 95: 381-387.
8. Gelfond D, Borowitz D. Gastrointestinal complications of cystic fibrosis. Clin Gastroenterol Hepatol 2013; 11: 333-342.
9. Zhang JT, Jiang XH, Xie C, Cheng H, Da Dong J, Wang Y et al. Downregulation of CFTR promotes epithelial-to-mesenchymal transition and is associated with poor prognosis of breast cancer. Biochim Biophys Acta 2013; 1833: 2961-2969.
10. Xie C, Jiang XH, Zhang JT, Sun TT, Dong JD, Sanders AJ et al. CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer. Oncogene 2013; 32: 2282-2291, 2291.e1-7.
11. Sun TT, Wang Y, Cheng H, Xiao HZ, Xiang JJ, Zhang JT et al. Disrupted interaction between CFTR and AF-6/afadin aggravates malignant phenotypes of colon cancer. Biochim Biophys Acta 2014; 1843: 618-628.
12. Oh SC, Park YY, Park ES, Lim JY, Kim SM, Kim SB et al. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut 2012; 61: 1291-1298.
13. Billings JL, Dunitz JM, McAllister S, Herzog T, Bobr A, Khoruts A. Early colon screening of adult patients with cystic fibrosis reveals high incidence of adenomatous colon polyps. J Clin Gastroenterol 2014; 48: e85-e88.
14. Wilke M, Buijs-Offerman RM, Aarbiou J, Colledge WH, Sheppard DN, Touqui L et al. Mouse models of cystic fibrosis: phenotypic analysis and research applications. J Cyst Fibros 2011; 10(Suppl 2): S152-S171.
15. Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 2009; 323: 1747-1750.
16. March HN, Rust AG, Wright NA, ten Hoeve J, de Ridder J, Eldridge M et al. Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet 2011; 43: 1202-1209.
17. Takeda H, Wei Z, Koso H, Rust AG, Yew CC, Mann MB et al. Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression. Nat Genet 2015; 47: 142-150.
18. Hodges CA, Cotton CU, Palmert MR, Drumm ML. Generation of a conditional null allele for Cftr in mice. Genesis 2008; 46: 546-552.
19. Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, Smithies O et al. An animal model for cystic fibrosis made by gene targeting. Science 1992; 257: 1083-1088.
20. Xu Z, Gupta V, Lei D, Holmes A, Carlson E, Gruenert DC. In-frame elimination of exon 10 in Cftrtm1Unc CF mice. Gene 1998; 211: 117-123.
21. De Lisle RC, Mueller R, Boyd M. Impaired mucosal barrier function in the small intestine of the cystic fibrosis mouse. J Pediatr Gastroenterol Nutr 2011; 53: 371-379.
22. Than BL, Goos JA, Sarver AL, O'Sullivan MG, Rod A, Starr TK et al. The role of KCNQ1 in mouse and human gastrointestinal cancers. Oncogene 2014; 33: 3861-3868.
23. de Sousa E, Melo F, Colak S, Buikhuisen J, Koster J, Cameron K et al. Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell 2011; 9: 476-485.
24. Merlos-Suárez A, Barriga FM, Jung P, Iglesias M, Céspedes MV, Rossell D et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011; 8: 511-524.
25. Munõz J, Stange DE, Schepers AG, van de Wetering M, Koo BK, Itzkovitz S et al. The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent '+4' cell markers. EMBO J 2012; 31: 3079-3091.
26. Van der Flier LG, Sabates-Bellver J, Oving I, Haegebarth A, De Palo M, Anti M et al. The intestinal Wnt/TCF signature. Gastroenterology 2007; 132: 628-632.
27. De Sousa E, Melo F, Wang X, Jansen M, Fessler E, Trinh A et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013; 19: 614-618.
28. De Lisle RC. Disrupted tight junctions in the small intestine of cystic fibrosis mice. Cell Tissue Res 2014; 355: 131-142.
29. Clarke LL, Gawenis LR, Bradford EM, Judd LM, Boyle KT, Simpson JE et al. Abnormal Paneth cell granule dissolution and compromised resistance to bacterial colonization in the intestine of CF mice. Am J Physiol Gastrointest Liver Physiol 2004; 286: G1050-G1058.
30. Norkina O, Kaur S, Ziemer D, De Lisle RC. Inflammation of the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2004; 286: G1032-G1041.
31. Munck A. Cystic fibrosis: evidence for gut inflammation. Int J Biochem Cell Biol 2014; 52: 180-183.
32. Juric M, Xiao F, Amasheh S, May O, Wahl K, Bantel H et al. Increased epithelial permeability is the primary cause for bicarbonate loss in inflamed murine colon. Inflamm Bowel Dis 2013; 19: 904-911.
33. Vij N, Mazur S, Zeitlin PL. CFTR is a negative regulator of NFkappaB mediated innate immune response. PLoS One 2009; 4: e4664.
34. Chen J, Jiang XH, Chen H, Guo JH, Tsang LL, Yu MK et al. CFTR negatively regulates cyclooxygenase-2-PGE(2) positive feedback loop in inflammation. J Cell Physiol 2012; 227: 2759-2766.
35. Burger-van Paassen N, Loonen LM, Witte-Bouma J, Korteland-van Male AM, de Bruijn AC, van der Sluis M et al. Mucin Muc2 deficiency and weaning influences the expression of the innate defense genes Reg3?, Reg3? and angiogenin-4. PLoS One 2012; 7: e38798.
36. Shan M, Gentile M, Yeiser JR, Walland AC, Bornstein VU, Chen K et al. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science 2013; 342: 447-453.
37. Schütte A, Ermund A, Becker-Pauly C, Johansson ME, Rodriguez-Pineiro AM, Bäckhed F et al. Microbial-induced meprin ? cleavage in MUC2 mucin and a functional CFTR channel are required to release anchored small intestinal mucus. Proc Natl Acad Sci USA 2014; 111: 12396-12401.
38. Garcia MA, Yang N, Quinton PM. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest 2009; 119: 2613-2622.
39. Dalerba P, Kalisky T, Sahoo D, Rajendran PS, Rothenberg ME, Leyrat AA et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol 2011; 29: 1120-1127.
40. Medema JP, Vermeulen L. Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nat Rev 2011; 474: 318-326.
41. Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A et al. Stromal contribution to the colorectal cancer transcriptome. Nat Genet 2015; 47: 312-319.
42. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013; 19: 619-625.
43. Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002; 295: 1726-1729.
44. Yang K, Popova NV, Yang W, Lozonschi I, Tadesse S, Kent S et al. Interaction of Muc2 and Apc on Wnt signaling and in intestinal tumorigenesis: potential role of chronic inflammation. Cancer Res 2008; 68: 7313-7322.
45. Denamur E, Chehab FF. Methylation status of CpG sites in the mouse and human CFTR promoters. DNA Cell Biol 1995; 14: 811-815.
46. Son JW, Kim YJ, Cho HM, Lee SY, Lee SM, Kang JK et al. Promoter hypermethylation of the CFTR gene and clinical/pathological features associated with non-small cell lung cancer. Respirology 2011; 16: 1203-1209.
47. Collawn JF, Fu L, Bartoszewski R, Matalon S. Rescuing ?F508 CFTR with trimethylangelicin, a dual-acting corrector and potentiator. Am J Physiol Lung Cell Mol Physiol 2014; 307: L431-L434.
48. Roth EK, Hirtz S, Duerr J, Wenning D, Eichler I, Seydewitz HH et al. The K+ channel opener 1-EBIO potentiates residual function of mutant CFTR in rectal biopsies from cystic fibrosis patients. PLoS One 2011; 6: e24445.
49. Clarke LL, Gawenis LR, Franklin CL, Harline MC. Increased survival of CFTR knockout mice with an oral osmotic laxative. Lab Anim Sci 1996; 46: 612-618.
50. Fijneman RJ, Anderson RA, Richards E, Liu J, Tijssen M, Meijer GA et al. Runx1 is a tumor suppressor gene in the mouse gastrointestinal tract. Cancer Sci 2012; 103: 593-599.
51. Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, Russell R et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 2003; 124: 762-777.
52. IPA Ingenuity Systems. Available at http://www.ingenuity.com (Accessed 2 February 2013).
53. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
54. Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 2011; 141: 1762-1772.